Thierry Bernard, CEO of Qiagen has been elected Chair of the AdvaMedDx Board of Directors. AdvaMedDx is a division of AdvaMed representing more than 75 manufacturers of in vitro diagnostic (IVD) tests and technologies in the U.S. and abroad.
Bernard joined Qiagen in 2015 and was named CEO in 2019. Previously, he worked for 15 years at bioMérieux, where he served in several roles, including as Corporate Vice President, Global Commercial Operations, Investor Relations, and the Greater China Region.
“Today, AdvaMedDx is well positioned and has the opportunity to ensure that patients and providers have access to reliable, precise diagnostics,” said Bernard. “I am excited to lead the AdvaMedDx Board of Directors, and I look forward to working with my colleagues to continue to make a meaningful impact on the diagnostics landscape and improve the lives of countless individuals around the world.”
“I am honored to welcome Thierry Bernard as the new chair of the AdvaMedDx Board. With his decades of experience, Thierry brings a clear vision of the work we can accomplish, and I look forward to working with him and the Dx Board to strengthen our healthcare system, especially as we come out of the pandemic,” said Scott Whitaker, President and CEO of Advamed. “For last two years, Norman Schwartz deftly led the Dx Board as the industry rose to meet the unprecedented demand for reliable and accurate diagnostic tests during the pandemic. Thanks to his leadership, this will be strong year for the industry and the patients we serve.”